LMAT
LeMaitre Vascular, Inc.
LMAT has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over LMAT overall, supported by stronger fundamentals.
LMAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
LMAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
LMAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 25x | $77.65 | — |
| Current | 28x | $77.65 | — |
| Cheap | 35x | $97.74 | +26% |
| Fair | 43x | $118 | +52% |
| Expensive | 52x | $143 | +85% |
Historical ranges are pointers, not guarantees.
LMAT's PE is in its cheap range at 28x. If earnings grow as analysts expect, today's price would be 25x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over LMAT in the historical PE scenario, which offers more potential upside but is not a forecast.
LMAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for LMAT, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over LMAT on the outlook, with more favorable profitability expectations.
LMAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.08 | +12% |
| Q3 2026 | $2.76 | +19% |
| Q2 2026 | $2.86 | +40% |
| Q1 2026 | $2.72 | +38% |
| Q4 2025 | $2.52 | +31% |
| Q3 2025 | $2.31 | +26% |
| Q2 2025 | $2.05 | +23% |
| Q1 2025 | $1.97 | +30% |
| Q4 2024 | $1.93 | +44% |
LMAT has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
LMAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $68M | +11% |
| Q2 2026 | $70.4M | +9.6% |
| Q1 2026 | $66.6M | +11% |
| Q4 2025 | $64.5M | +16% |
| Q3 2025 | $61M | +11% |
| Q2 2025 | $64.2M | +15% |
| Q1 2025 | $59.9M | +12% |
| Q4 2024 | $55.7M | +14% |
LMAT's revenue has grown year over year every quarter since late 2020: $68M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -7.2 points |
| Q2 2026 | 29% | +3.9 points |
| Q1 2026 | 27% | +5.6 points |
| Q4 2025 | 29% | +6.1 points |
| Q3 2025 | 33% | +9.3 points |
| Q2 2025 | 25% | -0.6 points |
| Q1 2025 | 21% | -1.1 points |
| Q4 2024 | 23% | +2.2 points |
LMAT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over LMAT on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
LMAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $19.7M | -26% |
| Q2 2026 | $13.7M | -28% |
| Q1 2026 | $12.3M | +61% |
| Q4 2025 | $21.4M | +63% |
| Q3 2025 | $26.5M | +111% |
| Q2 2025 | $18.9M | +145% |
| Q1 2025 | $7.7M | +107% |
| Q4 2024 | $13.1M | +39% |
LMAT's free cash flow has been positive every quarter for seven years: $67M over the past year, up 1.2% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
LMAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -6% | -1.5M shares |
| 1 year | -5.4% | -1.3M shares |
| 3 years | +2.6% | +590K shares |
| 5 years | +5.2% | +1.1M shares |
| Available history | +14% | +2.7M shares |
LMAT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $17,000 |
| Q1 2026 | $460,000 |
| Q4 2025 | $1.2M |
| Q3 2025 | — |
| Q2 2025 | $4,000 |
| Q1 2025 | $601,000 |
| Q4 2024 | $1.4M |
LMAT has spent almost nothing on buybacks in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LMAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.4x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
LMAT has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over LMAT on leverage, with a lower net debt burden relative to earnings.
LMAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 7.0 | Oversold |
LMAT's weekly RSI is 37 (neutral) and its Stochastic is 7 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
LMAT PE vs Healthcare Sector
| Metric | LMAT | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 8.8% above |
| PE % | 3 | 29 | 26 pts below |
LMAT is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over LMAT on valuation relative to its sector.
LMAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $80.7 | 3.8% below |
| 20 week MA | $85.8 | 9.5% below |
| 50 week MA | $92.4 | 16% below |
| 100 week MA | $90.2 | 14% below |
| 200 week MA | $79.0 | 1.7% below |
LMAT is in a downtrend: it's below all five of its weekly moving averages, and 1.7% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over LMAT on trend strength, trading above more of its moving averages.
LMAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.2 | $38.4 | +6.1% |
| 2021 | $38.4 | $51.5 | +34% |
| 2022 | $51.5 | $45.8 | -11% |
| 2023 | $45.8 | $56.8 | +24% |
| 2024 | $56.8 | $92.8 | +64% |
| 2025 | $92.8 | $83.8 | -9.8% |
| 2026 YTD | $83.8 | $77.7 | -7.3% |
LMAT has finished higher in four of the last six years. It's down 7.3% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over LMAT on returns for 2026, with the stronger performance.